Prospective Observational Study On Safety And Effectiveness Of Trastuzumabin Her- 2 Positive Breast Cancer Patients

Abstract

Introduction: Targeting HER-2 receptor cells with the targeted medication trastuzumab, which inhibits the proliferation of cancer cells, is used clinically for HER-2-positive breast cancer patients. Although it is used to treat several other types of cancer, HER-2-positive breast cancer patients benefit more from it. The effectiveness and safety of trastuzumab are the main topics of the study. With few adverse events reported, this therapy is typically well tolerated.

Methods: A total of 35 HER-2 positive breast cancer patients with consent were enrolled, and their trastuzumab treatment was evaluated for its effectiveness and safety. Naranjo Causality Assessment Scale, Uppsala Monitoring Scales, Hartwig severity scale and Common Terminology Criteria for Adverse Event (CTCAE) questionnaires were used to assess its safety and effectiveness. With the aid of IBM SPSS, the outcomes will be documented.

Results:Patients who chose trastuzumab as either an adjuvant or neoadjuvant therapy for HER-2-positive breast cancer underwent a six-month follow-up. On average, the tumour size has decreased or shrunk in 34 out of 35 individuals. Only 19% of patients exhibited grade 1 or 2 (asymptomatic) LV impairment as a result of concomitant therapy, while 47% of patients had normal cardiac function. Infusion responses were more common, affecting 50% of the study  population, and they were grade 1 during the first cycleof drug administration. Grade 2 neutropenia was observed in 3 patients. Grade 1 or 2 thrombocytopenia was caused by a reduced platelet count in 30% of individuals. 80% of the study's participants were leukaemia-free.

Conclusion:In our research population, the risk of disease progression or mortality was essentially non-existent among patients with HER-2-positive breast cancer who received trastuzumab. ADR occurred were of grade 1 and 2 which doesn’t interfere with the normal quality of life. The tumour size decrease was observed in 97% of study population, which is significant proof that trastuzumab is a safe and efficient in treatment of HER-2 positive breast cancer.